Lenacapavir PrEP roll-out begins in Africa

The Lancet HIV · Published 2026-04-24 · DOI 10.1016/s2352-3018(26)00103-7

Authors being retrieved — see the publisher record. https://doi.org/10.1016/s2352-3018(26)00103-7

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Viral load data from South Africa builds confidence in U=U · The Lancet HIV · 2026 · Same journal
• Invisible populations: SOGI data and HIV drug safety · The Lancet HIV · 2026 · Same journal
• The vaginal microbiome and HIV acquisition risk · The Lancet HIV · 2026 · Same journal
• Caregivers and healthy ageing with HIV in low-income and middle-income countries · The Lancet HIV · 2026 · Same journal
• Are screening periods in ART-naive trials justified in the era of rapid ART? · The Lancet HIV · 2026 · Same journal
• Durability of HIV viral suppression in South Africa: a national cohort study · The Lancet HIV · 2026 · Same journal
• Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study · The Lancet HIV · 2026 · Same journal
• HIV outbreaks in Pakistan: a health-care-acquired crisis · The Lancet HIV · 2026 · Same journal
• Trends in incidence of HIV and other sexually transmissible infections among transgender people in Australia: a retrospective 10-year national clinical cohort study · The Lancet HIV · 2026 · Same journal
• Cost-effectiveness of emergency department opt-out testing for HIV in England: a modelling study · The Lancet HIV · 2026 · Same journal